Pharmaceutical

FDA approves Biocon Biologics’ bevacizumab biosimilar for cancer

Biocon Biologics has received approval from the US Food and Drug Administration for the intravenous use of Jobevne (bevacizumab-nwgd).

Apr 12, 2025 - 06:00
FDA approves Biocon Biologics’ bevacizumab biosimilar for cancer
Biocon Biologics has received approval from the US Food and Drug Administration for the intravenous use of Jobevne (bevacizumab-nwgd).
Read the original article

Tags:

Previous Article

Can AI replace medical writers? Experts say not immediately

Next Article

Keros Therapeutics considers sale amid investor pressure

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: HCA, Louisiana hospital system sue FTC over review of hospital deal

STAT+: HCA, Louisiana hospital system sue FTC over revi...

Apr 21, 2023

STAT+: A new mom’s illness led to the first diagnosis of a rare condition after childbirth

STAT+: A new mom’s illness led to the first diagnosis o...

Aug 17, 2023

FDA accepts Sentynl’s Menkes disease therapy NDA for priority review

FDA accepts Sentynl’s Menkes disease therapy NDA for pr...

Jan 8, 2025